Stratified falsifiers should govern AD Master Plan preregistration: APOE

Target: AD Composite Score: 0.591 Price: $0.59 Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
⚠ Missing Evidence⚠ Low Validation Senate Quality Gates →
Evidence Strength Pending (0%)
0
Citations
1
Debates
1
Supporting
1
Opposing
Quality Report Card click to collapse
C+
Composite: 0.591
Top 46% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B Mech. Plausibility 15% 0.61 Top 55%
C+ Evidence Strength 15% 0.54 Top 52%
C+ Novelty 12% 0.59 Top 72%
B+ Feasibility 12% 0.74 Top 32%
C+ Impact 12% 0.50 Top 84%
C Druggability 10% 0.43 Top 78%
C+ Safety Profile 8% 0.59 Top 42%
C+ Competition 6% 0.53 Top 74%
B Data Availability 5% 0.68 Top 40%
B+ Reproducibility 5% 0.70 Top 24%
Evidence
1 supporting | 1 opposing
Citation quality: 0%
Debates
1 session B
Avg quality: 0.64
Convergence
0.00 F 4 related hypothesis share this target

From Analysis:

AD Master Plan preregistration: APOE

APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to APOE3 reduces amyloid and restores synaptic function

→ View full analysis & debate transcript

Description

Claims from this analysis should be evaluated across APOE, AD, tau, amyloid; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.61 (15%) Evidence 0.54 (15%) Novelty 0.59 (12%) Feasibility 0.74 (12%) Impact 0.50 (12%) Druggability 0.43 (10%) Safety 0.59 (8%) Competition 0.53 (6%) Data Avail. 0.68 (5%) Reproducible 0.70 (5%) KG Connect 0.50 (8%) 0.591 composite
2 citations 0 with PMID Validation: 0% 1 supporting / 1 opposing
For (1)
No supporting evidence
No opposing evidence
(1) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
MECH 2CLIN 0GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
The analysis question names specific entities or e…SupportingMECHAD-MASTER-PLAN-…-----
The current record can still be confounded by stag…OpposingMECHAD-MASTER-PLAN-…-----
Legacy Card View — expandable citation cards

Supporting Evidence 1

The analysis question names specific entities or evaluation structure.
AD-MASTER-PLAN-APOE-20260428030754

Opposing Evidence 1

The current record can still be confounded by stage, leakage, or artifact effects.
AD-MASTER-PLAN-APOE-20260428030754
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-28 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Theorist position for analysis AD-MASTER-PLAN-APOE-20260428030754: AD Master Plan preregistration: APOE

Context: Preregistered claim: APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to APOE3 reduces amyloid and restores synaptic function

Primary claim: APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan preregistration, th

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Skeptic critique for analysis AD-MASTER-PLAN-APOE-20260428030754: AD Master Plan preregistration: APOE

The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic causality.

The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across A

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Domain expert assessment for analysis AD-MASTER-PLAN-APOE-20260428030754: AD Master Plan preregistration: APOE

The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.

Feasibility is modera

Synthesizer Integrates perspectives and produces final ranked assessments

{
"ranked_hypotheses": [
{
"title": "APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology requires proximal validation",
"description": "The debate supports carrying forward APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology only if a proximal endpoint changes before the late outcome. The decisive validation path is: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts.",
"target_gene": "APOE",
"dimension_scores": {

Price History

No price history recorded yet

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (0)

No linked papers yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
32.3th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
0

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.641

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for AD.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for AD →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Related Hypotheses

Stratified falsifiers should govern AD Master Plan preregistration: TREM2
Score: 0.591 | neurodegeneration
Stratified falsifiers should govern AD Master Plan preregistration: LRP1
Score: 0.591 | neurodegeneration
Stratified falsifiers should govern AD Master Plan preregistration: GFAP
Score: 0.591 | neurodegeneration
Stratified falsifiers should govern AD Master Plan preregistration: BDNF
Score: 0.591 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 AD — Search for structure Click to search RCSB PDB
🔍 Searching RCSB PDB for AD structures...
Querying Protein Data Bank API

Source Analysis

AD Master Plan preregistration: APOE

None | 2026-04-27 | prereg

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (2)

APOE4 lipid dysregulation and synaptic phagocytosis as early drivers o
Score: 0.60 · APOE
APOE should remain under review until replicated
Score: 0.58 · tau
→ View all analysis hypotheses
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.